Medtronic strengthens pacemaker line:
This article was originally published in Clinica
Executive Summary
Medtronic has entered into a non-exclusive sublicence with wireless data communication technology company LifeSync Corporation to gain its patent portfolio. The sublicence will allow Medtronic to use LifeSync's wireless ECG data communication system in connection with implantable devices for cardiac pacing, defibrillation, neurostimulation, gastrostimulation and urological stimulation. Fort Lauderdale, Florida-based LifeSync said that it grants sublicences for its intellectual property to third parties for uses that it does not intend to internally develop and commercialise, in a statement made on August 15. This is the second deal Medtronic has struck up in a week to boost, in particular, its range of pacemakers. The company bought MRI safety patents from Biophan on August 9 (see Clinica No 1269, p 10).
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.